ROCK (Rho-associated protein kinase), a downstream effector of RhoA, plays an important role in many cellular processes. Accumulating evidence has shown the involvement of ROCK activation in the pathogenesis of many diseases. However, a reagent capable of detecting ROCK activation directly is lacking. In the present study, we show autophosphorylation of ROCKII in an in vitro kinase reaction. The phosphorylation sites were identified by MS, and the major phosphorylation site was found to be at the highly conserved residue Ser 1366 . A phospho-specific antibody was generated that can specifically recognize ROCKII 
INTRODUCTION
ROCKs (Rho-associated protein kinases) belong to the AGC serine/threonine protein kinase family [1] and play key roles in many cellular processes, including cell migration, apoptosis, centrosome duplication and cytokinesis [2] [3] [4] [5] [6] [7] . Two ROCK isoforms have been identified in mammals: ROCKI and ROCKII [8, 9] . They are composed of a kinase domain in the N-terminus, an RBD (Rho-binding domain) and a PH (pleckstrin homology) domain in the C-terminal region, which folds back on to the kinase domain to form an autoinhibitory loop that maintains ROCK in an inactive state [10] . The binding of GTP-bound RhoA to the RBD of ROCK disrupts this negative interaction, switching on ROCK activation [8, 11] , and its RhoA-binding affinity is regulated by Src-dependent phosphorylation [12] . In addition to RhoA binding, ROCK can be activated through proteolytic cleavage of the C-terminal inhibitory domain in apoptotic cells [13] [14] [15] or by intracellular second messengers, such as arachidonic acid [16, 17] . ROCK kinase activity is also regulated through interaction with several proteins, such as stimulation by Polo-like kinase-1 and nucleophosmin [7, 18] , and repression by Gem, Rad and Morgana [19, 20] . Thus various signalling pathways modulate ROCK activity.
ROCK activation leads to phosphorylation of various substrates, one of which is MLC (myosin light chain) [1, 3] . ROCK phosphorylates MLC directly and regulates the amount of phosphorylated MLC indirectly by inactivating MLCP (MLC phosphatase) through the phosphorylation of its MBS (myosinbinding subunit) [21, 22] . As a result, myosin II ATPase is activated to generate actomyosin contractility, thus contributing to RhoAinduced stress fibres and focal adhesions in fibroblasts [23, 24] . Cancer cells have been shown to respond to microenvironmental cues, such as matrix stiffness or inflammation signals, to increase ROCK-mediated actomyosin contractility as a driving force in tumour growth and invasion in tissues [25] [26] [27] [28] [29] . Given that stiffer tissues associated with hepatocarcinoma and breast cancer development involve ROCK activation, inhibition of ROCK reduces metastasis in hepatoma and breast tumour models [30] [31] [32] . Similar effects have also been shown in other cancer types, such as leukaemia, melanoma, and prostate and lung cancer [30, [33] [34] [35] . In addition to cancers, many clinical trials using the ROCK inhibitor fasudil have shown significant therapeutic effects on cardiovascular and neurological diseases [2, [36] [37] [38] . All of these results suggest the importance of ROCK activity in the pathogenesis of many diseases. However, whether ROCK activity is higher in these diseased tissues than in normal counterparts remains unknown.
Despite the importance of ROCK functions, a reagent that can assess ROCK activation directly in tissues or cells is lacking. Currently, ROCK activation can be detected directly by in vitro kinase assay [39] or indirectly by determining the inhibitorsensitive phosphorylation of its downstream substrates, such as MLC, MBS, LIMK (LIM kinase) and α-adducin [40] . However, none of these markers reflects ROCK activation status directly in cell and tissue samples. In the present study, we identified ROCK inhibitor-sensitive autophosphorylation sites in an in vitro kinase reaction and generated a phospho-specific antibody to reveal ROCKII activation. We found that Ser 1366 phosphorylation of ROCKII reflects its kinase activation and provides a direct way for assessing the extent of ROCKII activation in disease progression. Immunoprecipitation and in vitro kinase reaction myc-ROCKII-expressing cells were harvested in an immunoprecipitation buffer (1 % Nonidet P40, 5 % glycerol, 50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM PMSF and protease inhibitor cocktail). After pre-clearance, the lysates were incubated with anti-myc antibody at 4
• C for 60 min, and then precipitated with Protein A-agarose beads for 30 min. The immunoprecipitates were pre-incubated with or without 100 μM Y27632, which was followed by incubation with a 1× kinase buffer [50 mM Tris/HCl, pH 7.4, 10 mM MgCl 2 , 1 mM EGTA, 0.5 mM DTT (dithiothreitol), 5 mM NaF, 0.1 mM Na 3 VO 4 and 20 μM ATP] containing 5 μCi of [γ - 32 P]ATP at 30
• C for 20 min. The kinase catalytic activity of myc-ROCKII was measured as described previously [41] . Briefly, the immunoprecipitates were pre-incubated with or without 1 μM GTP[S] (guanosine 5-[γ -thio]triphosphate)-loaded GST-RhoA in 1× kinase buffer for 5 min. The kinase reaction was started by adding 2.5 μg of myelin basic protein and 5 μCi of [γ -
32 P]ATP. After incubation at 30
• C for 20 min, 5 μl of reaction mixture was spotted on to P81 paper (Whatman), and the papers were washed five times with 0.75 % phosphoric acid. Incorporation of 32 P into substrate was determined by scintillation counting. The immunoprecipitates from non-transfected cells (MOCK) was used as background. The protein levels of myc-ROCKII was detected by Western blotting with anti-myc antibody.
In-gel digestion and LC (liquid chromatography)-MS/MS (tandem MS)
The protein band corresponding to myc-ROCKII was excised from the gel for protease digestion as described by Tsay et al. [42] . In brief, proteins were digested with Lys-C, Arg-C or Asp-N (multiple enzymes used to increase sequence coverage), and the peptides were extracted with 0.1 % formic acid. Electrospray ionization-ion-trap-MS/MS was performed using a Thermo Finnigan LTQ Orbitrap tandem mass spectrometer interfaced with an Agilent 1100D HPLC system (Proteomes Research Center, Yang-Ming University). The spectra for the eluate were acquired as successive sets of scan modes described by Tsay et al. [42] , which included (i) identification of phosphopeptides on selected ion tracings on the basis of their elution behaviour, (ii) mapping phosphoamino acids within the sequence by CID (collisioninduced dissociation) experiments, and (iii) using the selected ion tracing method to quantitatively determine the phosphorylation states of myc-ROCKII proteins.
RhoA-ROCK interaction assay
Interaction between RhoA and ROCKII was measured as described previously [41] . Briefly, cells expressing myc-ROCKII were harvested and lysed with buffer (0.2 % Nonidet P40, 20 mM Tris/HCl, pH 7.4, 20 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 1 mM DTT, 50 mM NaF, 2 mM Na 3 VO 4 , 1 mM PMSF, 10 % glycerol and protease inhibitor cocktail). Pre-cleared supernatants were incubated with different amounts (0-5 μg) of GTP[S]-loaded GST-RhoA protein for 15 min and followed by incubation with glutathione beads at 4
• C for another 20 min. After extensive washing, myc-ROCKII pulled down by GTP[S]-GST-RhoA was detected by Western blotting with anti-myc antibody.
Phospho-specific antibody generation
The polyclonal anti-(pSer 1366 ROCKII) antibody was raised using phosphopeptide containing pSer 1366 of ROCKII conjugated with KLH (keyhole-limpet haemocyanin) as an antigen to immunize rabbits. Antisera were collected and sequentially affinity purified by phosphopeptide-and non-phosphopeptideconjugated columns (GTX122651; ICON Biotechnology).
IHC (immunohistochemical) staining
Specimens used for immunohistochemistry followed ethical standards of the Helsinki Declaration of 2008 and the Institutional Review Board of Taipei Veterans General Hospital. The tumour part and non-tumour part of the breast tissue blocks were embedded in Tissue-Tek OCT TM compound, snap-frozen and sectioned into 5 μm cryosections. The sections were fixed with 4 % (w/v) paraformaldehyde for 15 min and placed in boiling citrate buffer for 10 min. Endogenous peroxidase activity was quenched by 3 % H 2 O 2 for 10 min and this was followed by incubation with 5.5 % (v/v) normal goat serum in TBST (Trisbuffered saline containing 0.1 % Triton X-100) for blocking. Sections were subsequently incubated with primary antibody against pSer 1366 ROCKII (1:200 dilution; 5 μg/ml) in the presence or absence of the phosphopeptide or non-phosphopeptide (0.5 μg/ml). After extended washing, sections were incubated with HRP (horseradish peroxidase)-conjugated anti-rabbit antibody and then developed with DAB (diaminobenzidine) solution for 3 min. Slides were counterstained with haematoxylin, which was followed by dehydration then mounting.
RESULTS

Identification of Y27632-sensitive phosphorylation sites within ROCKII
Many protein kinases are autophosphorylated when they become active [43] [44] [45] . To determine whether this also occurs in ROCKII, myc-ROCKII protein overexpressed in HEK-293T cells was immunoprecipitated and subjected to an in vitro kinase reaction containing [γ -
32 P]ATP in the presence or absence of the ROCK inhibitor Y27632 [46] . Radioactively labelled ROCKII was detected and Y27632 treatment abolished the phosphorylation signal ( Figure 1A ). To identify phosphorylation sites, immunoprecipitated ROCKII was incubated with non-radioactive ATP in a kinase reaction, followed by SDS/PAGE separation. The protein band corresponding to myc-ROCKII ( Figure 1B ) was digested with Lys-C, Arg-C or Asp-N to increase the total sequence coverage (78.3 %) for LC-MS/MS analysis. Three Y27632-sensitive phosphopeptides were found ( Figure 1C) 
Characterization of autophosphorylation sites on ROCKII
We tested the contribution of Thr 1365 , Ser 1366 , Ser 1374 and Ser 1379 in the phosphorylation of myc-ROCKII carrying an alanine mutation in these sites. As shown in Figure 2(A) , the S1366A mutant gave a clear reduction in the intensity of [γ -
32 P]ATP labelling in contrast with no effect for the T1365A mutation, ruling out . We then performed a GTP[S]-GST-RhoA pull-down assay to determine whether in vitro autophosphorylation has an effect on ROCKII binding to the active form of RhoA. The WT and 4A mutant of myc-ROCKII exhibited similar RhoA-binding ability ( Figure 2B) . Furthermore, the in vitro kinase assay also indicated that unphosphorylatable (4A) and phosphomimetic (4E) myc-ROCKII mutants have similar catalytic activities when stimulated with GTP[S]-loaded GST-RhoA ( Figure 2C ). Thus in vitro phosphorylation of ROCKII at these sites has no effect on RhoA binding or catalytic function. 
An antibody to specifically recognize phosphorylation of Ser 1366 in ROCKII
To determine whether phosphorylation at Ser 1366 is a mark of active ROCKII in biological samples, we generated anti-(pSer 1366 ROCKII) antibody, which was capable of detecting the in vitro autophosphorylation of immunoprecipitated WT but not S1366A myc-ROCKII by Western blotting, and the signal was neutralized by phosphorylated peptide but not non-phosphorylated peptide ( Figure 3A) . Treatment of WT myc-ROCKII immunoprecipitates with λPPase (λ protein phosphatase) abolished the antibody detection signal (Figure 3B ), indicating its specificity in detecting phosphorylated ROCKII. Furthermore, the signal level of Ser 1366 -phosphorylated myc-ROCKII was markedly decreased in cells treated with Y27632 ( Figure 3C ).
We also found that ROCKI was autophosphorylated in the in vitro kinase reaction (see Supplementary Figure S1 at http://www. BiochemJ.org/bj/443/bj4430145add.htm). The sequence of human ROCKI corresponding to the region surrounding Ser 1366 of ROCKII shows 50 % identity ( Figure 3D ). We immunoprecipitated FLAG-ROCKI and FLAG-ROCKII proteins expressed in cells for Western blot analysis using anti-(pSer 1366 ROCKII) antibody. The result showed no cross-reactivity of anti-(pSer 1366 ROCKII) antibody to ROCKI ( Figure 3E ). All of these results suggest that the antibody specifically recognizes ROCKII Ser 1366 phosphorylation.
Detecting endogenous ROCKII activation by probing Ser 1366 phosphorylation
Next, we tested whether Ser 1366 phosphorylation on endogenous ROCKII can be detected in response to RhoA activation in cells. We found that the level of Ser 1366 phosphorylation of ROCKII in HEK-293T cells was increased by expression of constitutively active GFP (green fluorescent protein)-RhoAV14. In contrast, neither GFP-RhoAV14E40L, a constitutively active mutant of RhoA defective in its interaction with ROCK [47] , nor a dominant-negative form of GFP-RhoAN19 altered the level of ROCKII Ser 1366 phosphorylation ( Figure 4A) . Depletion of the endogenous ROCKII by siRNA transfection diminished the staining signal, confirming that the signal derived from ROCKII ( Figure 4B ). These results demonstrated that specific activation of endogenous ROCKII by RhoA leads to an increase in Ser 1366 phosphorylation. Thus RhoA-mediated ROCKII activation in cells can be specifically detected by Western blotting with the anti-(pSer 1366 ROCKII) antibody. We also examined the level of Ser 1366 phosphorylation of ROCKII in MEFs that were serum-starved and treated with LPA to activate the RhoA signal through a G-protein-coupled receptor [23] . We found that LPA treatment for 15 min increased Ser 1366 phosphorylation of ROCKII and co-treatment with Y27632 prevented Ser 1366 phosphorylation as expected, coinciding with MLC phosphorylation (Figure 5A) . Similarly, treatment with Having demonstrated ROCKII Ser 1366 phosphorylation in a cellular setting, we next used this anti-(pSer 1366 ROCKII) antibody to test whether ROCKII Ser 1366 phosphorylation could be detected in tissues by IHC staining. Since several reports have suggested the involvement of ROCK activation in breast cancer [30, 32] , the frozen breast tissues from two patients with breast cancer were used to test the IHC application of anti-(pSer 1366 ROCKII) antibody. We found that the ROCKII Ser phosphorylation signal was detectable and pronounced in the patient specimens from the tumorous tissue, whereas the signal in the non-tumorous tissue was weak (see Supplementary Figure S2 at http://www.BiochemJ.org/bj/443/bj4430145add.htm). Figure 5 ). Since MLC is also a substrate of MLC kinase, the increase in Ser 1366 phosphorylation level can be a more direct readout of ROCKII activation.
We have reported previously that Tyr 722 phosphorylation affects the binding affinity of ROCKII for RhoA [41] . In the present study, we found that autophosphorylation does not affect myc-ROCKII binding with RhoA. However, whether these autophosphorylations have a functional effect on protein targeting or protein-protein interaction in vivo remains to be investigated. Also unknown is whether these phosphorylation events take place intramolecularly or intermolecularly.
The importance of ROCK in pathogenesis is shown by using its specific inhibitors to interfere with disease progression in clinical trials and animal experiments. Liu et al. [32] reported that the levels of ROCKI and ROCKII transcripts of metastatic cells in bone cores were significantly higher than cells from primary tumours at the orthotropic site in a "human breast cancer metastasis to human bone" mouse model. Given that application of a ROCK inhibitor reduced cells metastasizing to bone in vivo, the increase in ROCK function makes a critical contribution to cancer progression [32] . In the present study, we also detected Ser 1366 phosphorylation in human breast cancer tissues, indicating its feasibility as a marker in clinical diagnosis. Moreover, the surrounding sequence covering Ser 1366 of ROCKII is highly conserved among different species of mammals, allowing probing of Ser 1366 phosphorylation in tissues in the mouse model experiments. In fact, we were able to detect positive signals by IHC staining in cirrhosis of the liver in rat ( [50] and results not shown). Given the existence of another ROCK isoform, it is possible to apply the same approach to define phosphorylation sites for assessing the activation status of ROCKI in cell and tissue samples. The specific antibodies against phosphorylated ROCKs that mark activation will provide valuable tools for evaluation of ROCK activation in disease progression. IHC staining results of pSer 1366 ROCKII in frozen breast tissues. The tumorous and non-tumorous tissue blocks from two breast cancer patients were sectioned and stained with anti-(pSer 1366 ROCKII) antibody in the presence of the phosphopeptide or non-phosphopetide as indicated. IHC staining with normal rabbit IgG in tumorous specimens is shown as a negative control. Haematoxylin was used for counterstaining. The images were acquired with a ×10 (upper panels) or ×40 (lower panels) lens. Both samples are oestrogen receptor-positive invasive ductal cancer. #1 is lymph node-negative and #2 is lymph node-positive.
